OncoMatch/Clinical Trials/NCT07021898
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Is NCT07021898 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ERAS-4001 and ERAS-4001 in combination for metastatic solid tumors.
Treatment: ERAS-4001 · ERAS-4001 in combination — The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IV
Metastatic disease required
Advanced or metastatic solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: ras inhibitor
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiovascular function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute (SCRI) Oncology Partners · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
- NEXT Oncology · Irving, Texas
- NEXT Oncology · San Antonio, Texas
- Fred Hutchinson Cancer Center · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify